{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:46:43Z","timestamp":1789778803512,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.amjcard.2019.07.067","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T01:56:35Z","timestamp":1566525395000},"page":"1630-1635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Infliximab for Refractory Cardiac Sarcoidosis"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-0251","authenticated-orcid":false,"given":"Logan J.","family":"Harper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghann","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L.","family":"Ribeiro Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Hachamovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Shaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brunken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.07.067_bib0001","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Hear Rhythm"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0002","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1034\/j.1399-3003.1999.14d02.x","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis","volume":"14","author":"Costabel","year":"1999","journal-title":"Eur Respir J"},{"issue":"Suppl 5","key":"10.1016\/j.amjcard.2019.07.067_bib0003","first-page":"v1","article-title":"Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0004","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0005","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0006","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0007","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0008","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis, Vasc Diffus Lung Dis"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0009","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/17476348.2017.1289842","article-title":"Sarcoidosis: treatments beyond prednisone and methotrexate","volume":"11","author":"Ribeiro Neto","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0010","first-page":"50","article-title":"Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis","volume":"28","author":"Isiguzo","year":"2011","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe {\u2026}","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0013","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10067-007-0614-1","article-title":"Cardiac sarcoidosis responding to monotherapy with infliximab","volume":"26","author":"Uthman","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0014","first-page":"509","article-title":"Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases","volume":"33","author":"Chapelon-Abric","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres","author":"Fussner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0016","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","article-title":"RISING study.Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study","volume":"19","author":"Takeuchi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0017","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2006.065995","article-title":"Double-blinded infliximab dose escalation in patients with rheumatoid arthritis","volume":"66","author":"Rahman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjcard.2019.07.067_bib0018","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ibd.21886","article-title":"Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn\u02bcs disease","volume":"18","author":"Hibi","year":"2012","journal-title":"Inflamm Bowel Dis"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919309555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919309555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:30:41Z","timestamp":1757572241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919309555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0002914919309555"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.07.067","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab for Refractory Cardiac Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.07.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}